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Multiple sclerosis (MS) is a complex inflammatory disease of the central nervous system (CNS) resulting in neurological 
impairment and disability. There is evidence that adequate vitamin D levels may lower the risk of MS development. The 
aetiology of MS is complex and involves both genetic and environmental factors. In fact, not one but several genes are 
believed to lead to the disease. As for environmental factors, one of the most important risk factors is vitamin D deficiency, 
which, in turn, is closely related to gene polymorphisms that play a role in vitamin D metabolism and regulation. However, 
information about these gene polymorphisms is quite contradictory. The aim of this review is to discuss the association 
between some of the vitamin D-related gene variants and MS.
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Multiple sclerosis (MS) is a chronic, inflammatory, 
autoimmune, and demyelinating disease of the central 
nervous system (CNS). It is estimated that 2.1 million 
people have MS worldwide (1). MS is the most common 
neurodegenerative disorder of Caucasian 25 to 35-year-old 
adults. Women are affected three times more often than men 
(2). It starts as an autoimmune response to myelin proteins 
and other unidentified antigens that results in the 
demyelination and dense astrogliosis in the white matter of 
the brain (3). It is widely believed that the culprits for early 
demyelination in MS are T-cell-mediated autoimmune 
responses and oligodendrocyte apoptosis (4). Lymphocytes 
infiltrate the CNS and damage myelin and axons. The 
resulting neurodegeneration then leads to musculoskeletal 
dysfunction, muscle weakness and pain, visual problems, 
severe disability, and eventually death (5).
Although the aetiology of MS has not been fully 
elucidated, it is known that it involves an interaction 
between genetic, environmental, and geographical factors 
(6). Genetic epidemiological studies provide strong 
evidence that geographical localisation is highly related to 
MS prevalence. It increases as the latitude decreases, 
possibly due to low exposure to sun. Therefore, the areas 
with the highest risk are the north of the United States, 
northern Europe, Canada, southeastern Australia, and 
southeastern New Zealand. However, one of the countries 
with relatively high prevalence is also Israel (7), which 
suggests that geography is not the only factor contributing 
to the development of MS.
Low sun exposure is linked to low levels of vitamin D, 
and the primary source of vitamin D is ultraviolet B (UVB) 
light from the sun with a wavelength between 290 and 
315 nm, particularly in the summer (6).
The biologically active form of vitamin D is 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3), which is 
produced in several steps. A large proportion comes from 
the UVB-induced biotransformation of 7-dehydrocholesterol 
to vitamin D3, followed by two hydroxylation reactions. 
The first, the formation of vitamin D metabolite 
25-hydroxyvitamin D3 25(OH)D3 occurs in the liver. The 
second occurs in the kidneys, where the active metabolite, 
1,25(OH)2D3, is formed, enters the cell, and binds to the 
vitamin D receptor (VDR) (6, 8).
Most of the biological functions of vitamin D3 are 
mediated through VDR (6, 8). Monocytes, macrophages, 
dendritic cells, activated T and B cells are known to carry 
VDR on their surfaces. The major role of 1,25(OH)2D3 is 
to modulate immune response. Acting as a steroid hormone, 
vitamin D controls infections by enhancing the phagocytic 
and antibacterial activities of immune cells. Furthermore, 
vitamin D inhibits the production of pro-inflammatory 
cytokines (which play an important role in the development 
of many chronic autoimmune diseases) by stimulating 
regulatory T-cells and reducing T-cell proliferation. Several 
studies have shown that vitamin D helps the regulation of 
the immune system (9, 10). It is also essential for bone and 
calcium homeostasis (5).
Vitamin D deficiency, in turn, is believed to be 
associated with bone fractures, cognitive disorders, 
dementia, cancer, stroke, and neurodegenerative diseases, 
including MS (6, 11). The best indicator of vitamin D status 
is the serum 25(OH)D level. Levels below 30 nmol L-1 
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(12 ng mL-1) suggest vitamin D deficiency and 30-
50 nmol L-1 (12-20 ng mL-1) vitamin D insufficiency. Levels 
between 50 and 75 nmol L-1 (20-30 ng mL-1) are considered 
normal (12).
However, even though epidemiological studies 
demonstrate low serum vitamin D levels and high rates of 
bone fractures in MS patients (5, 13), what stands behind 
this association with MS is still not clear. Some researchers 
suggest that vitamin D deficiency increases the risk of MS 
by putting the immune system in a more pro-inflammatory 
state (6).
Case-control studies have shown that vitamin D levels 
are significantly lower in people with MS than in healthy 
controls. In one of those studies (14), 61 % of MS patients 
had vitamin D insufficiency. These findings raise the 
question of whether low vitamin D levels increase the risk 
of MS or is it vice versa, that MS decreases vitamin D levels. 
Is it, perhaps, that MS symptoms, which are exacerbated 
by heat, may lead to sun avoidance and result in lower 
vitamin D levels? Or is it that vitamin D deficiency/
insufficiency triggers MS (7)?
One argument against the first proposal is that gene 
variances in vitamin D metabolism can substantially affect 
serum vitamin D levels, despite sufficient UVB exposure. 
This is particularly true of the gene polymorphisms of drug 
metabolising enzymes and receptors. For example, single 
nucleotide polymorphisms (SNPs) of metabolising enzymes 
and VDR may modify how these proteins and the immune 
system work. In other words, polymorphisms of the genes 
involved in vitamin D regulation may affect susceptibility 
to MS development (6). And there are many gene 
polymorphisms of many immune receptors and drug carrier 
enzymes that contribute to MS.
The aim of this review was to discuss the most studied 
VDR and CYP450 gene polymorphisms and see how they 
are related to the development of MS in order to understand 
the functional consequences of these variations and find 
possible applications in risk assessment of the disease.
POLYMORPHISMS OF VITAMIN D 
METABOLISM GENES
VDR gene polymorphisms
VDR is an intracellular receptor that belongs to the 
steroid/thyroid nuclear receptor family and is found in 
various tissues, including brain, immune cells, and 
peripheral blood monocytes. The VDR gene is located on 
12q13.1, consists of 9 exons and 8 introns, and has 
numerous allelic variants (11). 11,25(OH)2D3 interacts 
with the VDR and then binds to the retinoid X receptor 
(RXR) to form a heterodimer complex. This heterodimer 
complex binds to the VDR response elements (VDRE) in 
the promoter region of the target genes in the nucleus. 
However, in the absence of 1,25(OH)2D3, VDR shuttles 
between the nucleus and cytoplasm instead of activating 
and translocating into the nucleus. Moreover, the 
heterodimer complex is not stable enough to bind to DNA, 
which results in repression of target gene transcription (15).
VDR gene variants can severely affect gene activation 
and disturb vitamin D and calcium metabolism, thereby 
increasing the risk of autoimmune diseases such as MS (1). 
Considering that recent research points to VDR SNPs in the 
development of MS, researchers are hoping to clarify the 
relationship between vitamin D and MS (15). Among over 
30 VDR SNPs (16) the most studied are FokI (rs10735810), 
BsmI (rs1544410), TaqI (rs731236), and ApaI (rs7975232). 
However, reports about the association between these four 
gene polymorphisms and MS risk are controversial (16-20).
BsmI (A/G substitution), TaqI (T/C substitution), and 
ApaI (G/T substitution) are located at the 3’ end of the VDR 
gene and do not result in any structural change of the VDR 
protein, but there is evidence that these polymorphisms may 
affect VDR function through altered activation of VDR 
expression (1, 4, 15, 21). However, only the FokI 
polymorphism has been associated with variations in 
vitamin D levels in MS patients (8, 15, 17, 22). The FokI 
polymorphism is located in the translation initiation site in 
exon 2 of the VDR gene and results in two different 
transition initiation sites in the VDR. T to C substitution in 
the first translation initiation codon ATG leads to long (ff) 
and short (FF) variants of the VDR protein (8).
FokI
The missense SNP of FokI does not to interfere with 
DNA binding, ligand binding, and heterodimer formation 
with the RXR. However, the F allele has higher 
transcriptional activity (1). It is reported that the f allele of 
FokI has a lower frequency in Africans than in European 
Caucasians and Asians (23). A case-control study (22) from 
the Netherlands with 212 MS patients and 289 healthy 
controls showed that the F (shorter) allele of FokI 
corresponded to significantly higher levels of 1,25(OH)2D3 
and significantly lower levels of 25(OH)D3 in the serum 
of MS patients compared to the f (longer) allele (p=0.034). 
Likewise, a Sicilian study with 104 MS patients and 75 
healthy controls determined low serum 25(OH)D3 levels 
in MS patients with the FF and the Ff genotypes compared 
to the MS patients with the ff genotype (8).
A study with north European Caucasians pointed to a 
lower expression of the ff genotype in MS patients (24). 
Beside the differences in transcriptional activity of the FokI 
variants, this polymorphism may also determine the severity 
of MS (15). In another study (25), in a total of 512 northern 
European Caucasians the f allele of FokI was associated 
with a milder disability after the onset of MS between 
individuals with the Expanded Disability Status Score 
(EDSS) <6 and those with EDSS ≥6. In another words, the 
f allele was associated with reduced risk of disability. These 
data indicate that the VDR FokI polymorphism has 
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with vitamin D insufficiency. Yet, another Greek study (5) 
reported an association between BsmI polymorphism and 
bone loss in patients with MS.
TaqI
TaqI is another VDR gene polymorphism studied for 
association with MS. In addition to reports of the strong 
correlation between TaqI and 25(OH)2D3 levels (22), 
several studies have corroborated its role in MS development. 
A Tunisian study (4) showed that the frequency of the T 
allele of TaqI was significantly lower in 60 MS patients 
than in 114 healthy controls, which suggests that it might 
protect against MS development (OR=0.52, 95% CI=0.3-
0.9, p=0.012). In contrast, the C allele of TaqI appeared to 
predispose for MS. However, these findings have not been 
confirmed by other Caucasian Spanish (18), southern 
Spanish (33), Greek (32), Canadian (28), Slovak (30), and 
Dutch (34) studies. They all show no differences in allelic 
variant frequencies between MS patients and healthy 
controls. Huang and Xie (16) believe that this disagreement 
is owed to ethnicity-specific genetic variations between the 
studied populations. Indeed, different frequencies of the T 
allele of TaqI have been reported for different ethnic groups, 
as follows: 60 % in the American population (17), 63 % in 
the Greek population (32), 65.5 % in the Caucasian Spanish 
population (29), and 82 % in the Tunisian population (4). 
The C allele of TaqI has been reported to have a lower 
frequency in Asians than in Africans and European 
Caucasians (23). Interestingly, an Australian Caucasian 
study (13) with 104 MS patients and 104 healthy controls, 
found that the otherwise rarer T allele (allele which is cut 
by TaqI enzyme) was more common in MS patients than 
in healthy controls. The risk of MS associated with it was 
at least twice as high as that in non-carriers (OR=2.35, 95% 
CI=1.29-4.27, p=0.0048). Furthermore, the T allele of TaqI 
involved a three times higher risk of MS. A higher frequency 
of the T allele of TaqI was also detected in 560 MS cases 
from United Kingdom and Australia in comparison to 480 
healthy controls (2).
On the other hand, TaqI and BsmI genotype distribution 
was significantly different in 50 MS patients than 50 healthy 
controls and was associated with MS risk in the Kuwaiti 
population (35).
ApaI
In general population the T allele of ApaI has a higher 
frequency in Asians and European Caucasians than in 
Africans (23). Findings about the association of ApaI 
polymorphisms with MS risk are also inconclusive. In a 
study of a Tunisian population (4), ApaI was not associated 
with MS risk; neither the allele nor the genotype frequency 
distribution significantly differed between MS patients and 
healthy controls (p>0.05). A study in Slovak (30) and 
Kuwaiti population (35) showed similar findings. The latter 
important consequences for vitamin D metabolism in both 
MS and healthy control subjects. However, there are several 
studies that did not find any significant link between the 
VDR polymorphism and vitamin D levels (26) or the risk 
of MS (2, 16, 17, 272, 16, 18, 24). An American study (17) 
found an association between the shorter, F allele 
(determined in 214 women with MS) and increased 
transcriptional activity, but no association between MS and 
vitamin D intake among these women (OR=0.93, 95 % 
CI=0.78-1.09). However, the study established a significantly 
lower risk of MS risk in women with the ff genotype who 
were taking vitamin D supplementation (RR=0.21, 95% 
CI=0.06-0.78, p=0.02) (17). Several other studies found no 
association between the VDR FokI polymorphism and risk 
of MS, such as those conducted in Canada (28), Australia 
(27), Iran (1, 11), and Spain (29).
BsmI
There are several studies showing a strong association 
between the VDR BsmI polymorphism and MS risk (1, 11, 
29). While in the Japanese population A allele is more 
common, a significantly higher frequency of the homozygote 
G allele (GG) was found in 77 MS patients compared to 95 
healthy controls (OR=2.38, 95% CI=1.11-5.11, p=0.026) 
(18). In contrast, a Slovak case-control study (30) did not 
observe any role of BsmI allelic variants in MS susceptibility 
among 270 MS patients (58.3 % G allele vs 41.7 % A allele) 
and 303 healthy controls (57.6 % G allele vs 42.4 % A 
allele). However, with a robust analysis they found a 
protective effect of the AA genotype against MS development 
when compared to the G allele (OR=0.59, 95% CI=0.39-0.9, 
p=0.014) (30). This protective effect is supported by the 
functional impact of the G allele of BsmI on the VDR gene 
expression. Another study reported that the G allele of BsmI 
decreases VDR mRNA expression (31). Therefore, the 
absence of the G allele or the presence of the AA genotype 
may result in normal or increased expression of VDR. A 
change in VDR expression may improve receptor function 
and signalling and thus enhance the protective effects of 
vitamin D against MS (30).
An Iranian study with 113 MS patients and 112 healthy 
controls confirmed the protective effect of the AA genotype 
of BsmI against MS development, and also found a positive 
association between the G allele and MS (OR=1.7, 95% 
CI=1.1-2.5, p=0.012) (11). Another Iranian study (1) 
confirmed the association between BsmI polymorphism and 
MS risk. Interestingly the AA genotype frequency in that 
study was higher in the 160 MS patients than in the 150 
healthy controls (OR=2.52, 95% CI=1.31-4.83, p=0.005; 
OR=1.88, 95% CI=1.35-2.6, p=0.0002, respectively).
In a sample population from northwestern Greece (32), 
no direct association was established between BsmI 
polymorphism and MS risk or bone mineral density (BMD). 
However, the study reported that lower BMD and increased 
frequency of osteoporosis in MS patients was associated 
Elkama A, Karahalil B. Role of gene polymorphisms in vitamin D metabolism and in multiple sclerosis 
Arh Hig Rada Toksikol 2018;69:25-31
28
study also found no association between ApaI and vitamin 
D levels.
In contrast, studies in Australian Caucasian (13) and 
Japanese populations (36) found a positive association 
between ApaI and the development of MS. In the Australian 
Caucasian study, the T allele of ApaI was significantly 
associated with MS (p<0.05) and there was a strong linkage 
disequilibrium between TaqI and ApaI variants (13). The 
Japanese study showed higher frequency of the T allele of 
ApaI and the TT genotype in 77 MS patients compared to 
95 healthy controls (p=0.032 and p=0.007, respectively) 
(36).
Cdx-2
A few studies have also investigated the association 
between Cdx-2 polymorphism, another SNP in the VDR 
gene, and MS. This polymorphism causes an A to G 
substitution in the 5’ UTR region of the gene and affects 
the function of the CDX2 transcription factor. Cdx-2 is 
primarily expressed in the gut, and autoimmune diseases, 
including MS, are assumed to be related with gut immunity. 
However, the association between MS development and 
reduced CDX activity in the gut is uncertain (27).
An Australian study (27) with 113 MS patients and 234 
healthy controls observed an increased MS risk in G allele 
carriers exposed to sunlight for less than one hour a day 
(OR=1.87; 95 % CI=1.07-3.28). Compared to the A allele, 
the G allele of Cdx-2 was associated with a 70 % reduction 
in transcriptional activity of the VDR gene promoter. On 
the other hand, the study did not find any significant 
association between MS risk and the GG genotype versus 
the AA genotype.
In contrast, a French study (19) conducted in MS 
patients and age- and sex-matched controls found no 
significant association between Cdx-2 and MS, but it did 
establish a threefold increase in MS risk in the carriers of 
maternal G allele and paternal A allele (OR=3.13, 95 % 
CI=1.3-7.7). A US Caucasian study also found no significant 
association between MS and Cdx-2 polymorphism 
(RR=0.97, 95 % CI=0.79-1.21) (17).
A study in middle-aged and elderly Chinese women 
(37), however, found an association between Cdx-2 
polymorphism and serum 25(OH)D levels and BMD.
Meta-analysis of the VDR gene polymorphisms
Meta-analysis provides more robust data than individual 
studies by compiling data from many studies to produce a 
large sample size. A recent meta-analysis (38) that included 
a total of 3300 MS patients and 3194 controls from 13 
case-control studies evaluated the four VDR genes, ApaI, 
TaqI, BsmI, and FokI and found that the homozygote AA 
genotype of ApaI and the FF genotype of FokI were 
significant risk factors for MS development, but found no 
such association for the BsmI and TaqI polymorphisms. 
This meta-analysis covers a wide range of ethnic groups, 
including Asians (from Japan), European Caucasians (from 
UK, Italy, Greece, and Spain), Australians (from Tasmania), 
Australian Caucasians (from Queensland), Netherlands 
Caucasians, and Caucasian Americans (from Boston, USA). 
The authors reported that the data were moderately 
heterogeneous due to ethnic differences, study periods, and 
geographical latitude.
Another meta-analysis (16), which covered the same 
studies save for two Spanish Caucasian studies, suggested 
that these four VDR gene polymorphisms were not 
associated with the risk of MS. The main reason for this 
result was the heterogeneity and inconsistencies between 
the studies, such as diagnosis of the disease, ethnic and 
geographical factors, sex, and different genotyping 
methods.
Interaction between HLA-DRB1 and the VDR gene 
polymorphisms
Environmental factors alone are not sufficient to explain 
why African American, Asian, or North American 
indigenous populations are more resistant to MS than 
Europeans, which, in turn, points to genetics (39). It is not 
easy to determine MS susceptibility in terms of association 
with one or two gene polymorphisms, since MS is a 
complex, polygenic heritable disorder.
However, Fernandez de Abreu et al. (19) have singled 
out HLA-DRB1 locus as the main susceptibility region and 
have provided a robust association between the risk of MS 
and HLA-DRB1 polymorphism. They have identified VDRE 
in the promoter region of HLA-DRB1 as the binding target 
for VDR. Cox et al. (2) suggest that HLA-DRB1 expression 
may be altered by 1,25(OH)2D3, the active form of vitamin 
D. In fact, they claim that HLA-DRB1*1501 carries the 
highest genetic risk of MS development.
There is growing evidence of a direct interaction 
between HLA-DRB1 and vitamin D as the main 
environmental contributor to MS. Studies (39, 40) suggest 
that the expression of HLA-DRB1 in the thymus is affected 
by vitamin D deficiency in childhood, and that the 
underexpression of the HLA-DRB1*1501 allele in the 
thymus might increase the risk of autoimmune diseases 
such as MS.
The MS-associated HLA-DRB1*1501 allele is not 
distributed equally among ethnicities; it is high in 
Caucasians and low in Africans and Asians. Moreover, it 
is more common in women with MS (39). This finding that 
the association between the HLA-DRB1*1501 allele and 
MS is specific for women has also been supported by Irizar 
et al. (33).
There are several other studies investigating the role of 
the HLA-DRB1*1501 allele alone and in combination with 
other VDR gene polymorphisms in MS susceptibility (27, 
33, 36, 20). A study in Australian Caucasians (27) showed 
a correlation between Cdx-2 and the HLA-DRB1*1501 
allele, with the HLA-DR15 locus having the strongest 
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association with MS susceptibility (OR=3.91, 95 % 
CI=2.34-6.56).
A study in a Japanese population (36) found that the 
combination of the T allele of ApaI and HLA-DRB1*1501 
allele increased the risk of MS (OR=2.069). They also 
suggested that the HLA and the VDR BsmI/ApaI alleles 
combined may have a role in the development of the disease.
Another study of 1360 MS patients and 1677 healthy 
controls in Canada showed that HLA-DRB1*15 carriers 
with the longer isoform T allele of FokI ran the higher risk 
of MS (p=0.034) (20).
CYP27B1 gene polymorphism
Cytochrome P450 CYP27B1 metabolising enzyme has 
also been investigated in MS susceptibility due to its 
importance in vitamin D3 activation. This enzyme regulates 
the level of biologically active vitamin D and plays an 
important role in calcium homeostasis (41). It codes for the 
25-hydroxy-vitamin D-1 alpha hydroxylase enzyme, which 
hydroxylates the inactive form 25(OH)D3 into its active 
form 1-25(OH)2D3. Therefore, its gene polymorphisms 
may alter vitamin D metabolism and, consequently, its 
regulatory role. Recently, the Australian and New Zealand 
Multiple Sclerosis Genetics Consortium (ANZ gene) 
reported a strong association between the CYP27B1 gene 
and MS (p=5.4x10-11) (42). This association was confirmed 
by Sundqvist et al. (43) in a Swedish population (2158 MS 
patients and 1759 healthy controls).
In contrast, Simon et al. (17) found no such association. 
Instead, they observed that the combination of dietary 
vitamin D supplementation and the VDR FokI ff genotype 
could reduce the risk of MS (p=0.02).
In summary, among the VDR variants, the FokI f, BsmI 
A, TaqI T, and ApaI G alleles have been singled out as 
protective against MS in most but not all studies, mostly 
due to ethnic differences. Furthermore, there are 
environmental factors to consider, along with the genetic 
ones. The HLA-DRB1*1501 allele is the most likely variant 
to be involved in MS, and its interaction with other genes 
involved in vitamin D metabolism has drawn scientific 
attention. CYP 450 gene polymorphisms have received less 
attention in this context and need further research.
CONCLUSION
So far, epidemiological studies have reported conflicting 
findings about gene polymorphisms involved in vitamin D 
metabolism and their association with MS. It is still unclear 
which and how many genes are involved in the development 
of MS, but it is pretty clear that research should focus on 
the ones that lead to vitamin D insufficiency. However, this 
does not complete the picture. In order to elucidate the 
mechanisms of MS development, other parameters 
participating in vitamin D metabolisms should be taken into 
account, such as co-factors, enzyme activities, and 
epigenetic regulation of genes involved in vitamin D 
metabolism. Furthermore, MS cannot be explained by any 
single factor alone, whether it is environmental or genetic. 
Future large genome-wide studies of gene-gene and gene-
environment interactions that include other risk parameters 
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31
Uloga genskih polimorfizama u metabolizmu vitamina D i multiploj sklerozi
Multipla skleroza složena je upalna bolest središnjeg živčanog sustava koja dovodi do neuroloških poremećaja i invalidnosti. 
Prema nekim istraživanjima, rizik od multiple skleroze manji je u osoba s dovoljnim razinama vitamina D. Etiologija 
bolesti je složena i obuhvaća nasljedne i okolišne čimbenike. Štoviše, vjeruje se da je više gena odgovorno za nastanak 
bolesti, a od okolišnih se čimbenika najviše izdvaja nedostatak vitamina D, što je opet povezano s genskim polimorfizmima 
koji su važni za regulaciju njegova metabolizma u tijelu. Dosadašnja saznanja o tim polimorfizmima i njihovoj ulozi, 
međutim, prilično su oprečna. Stoga je namjera ovoga preglednog članka raspraviti o mogućoj povezanosti između 
pojedinih varijanti gena za metabolizam vitamina D i nastanka multiple skleroze.
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